Allegria Therapeutics, a Basel, Switzerland-based company focused on advancing a pipeline of therapeutics for mast cell-mediated diseases, raised USD 3.5M in Seed funding.
Forty51 Ventures made the investment.
The company intends to use the funds to progress a differentiated portfolio of proprietary therapeutic approaches around targets that selectively modulate mast cells to more effectively address patients’ needs.
Allegria focuses on mast cells as mediators of allergy and inflammatory diseases, a class of indications that constitutes an increasing burden world-wide. The company collaborates with partners in fundamental mast cell biology, drug discovery and preclinical drug evaluation including Prof. Marcus Maurer, Managing Director of the Institute for Allergy Research at Berlin’s Charité and Dr. Philipp Starkl, Principal Investigator at the Medical University of Vienna.
Furthermore, the company announced the appointment of co-founder Maria van Dongen, PhD as Chief Executive Officer. Dr. van Dongen brings broad industry experience with a strong track record in Pharma. She previously held positions at amongst others Johnson & Johnson, where she facilitated external partnerships aiming at e.g., the effective targeting of RNA processing and the discovery of peptide-based therapeutics. Previously, she led numerous R&D projects that included the discovery of highly innovative orally active broad-spectrum influenza antivirals, and an R&D platform dedicated to pharmaceutical interventions for disease prevention.
FinSMEs
06/05/2024